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A B S T R A C TObjective: To compare the responsiveness of the EuroQol five-
dimensional questionnaire (EQ-5D) generic quality-of-life instrument
with that of specific instruments—the Brief Pain Inventory (BPI) and
the Oswestry Disability Index (ODI)—in assessing low back pain.
Methods: Data were obtained from a group of patients receiving
epidural steroid injections. We assessed responsiveness by using
correlation, by estimating standardized response means, by receiver
operating characteristic curve analysis, and by comparing the mini-
mum clinically important differences peculiar to each of the instru-
ments. Results: ODI, BPI, and EQ-5D index scores, and changes in
scores, were found to be correlated. Estimated standardized response
means and receiver operating characteristic curve analysis suggested
lower responsiveness for the EQ-5D index score. Clinically significant
categories of mild, moderate, and severe BPI pain intensity translated
into progressively and significantly lower mean EQ-5D index scores.
An increase or a decrease in severity level reported on any of the fivesee front matter Copyright & 2013, International
r Inc.
.1016/j.jval.2012.09.003
ynes@nottingham.ac.uk.
ondence to: David K. Whynes, School of EconomicsEQ-5D dimensions was associated with significant changes (with
appropriate signs) in the condition-specific scores. No change in
severity in any EQ-5D dimension was associated with no change in
the specific scores. Significant changes in the EQ-5D index scores were
associated with clinically important changes in the ODI and BPI
scores. Correlation between index scores and responses on EQ-5D’s
visual analogue scale was only moderate. Conclusions: The EQ-5D
index is less responsive than instruments specific to pain measure-
ment, although it is capable of indicating clinically important
changes. The lower responsiveness arises from EQ-5D’s more limited
gradation of severity and its multidimensionality.
Keywords: Brief Pain Inventory, EQ-5D, health state utility, low back
pain, Oswestry Disability Index, responsiveness.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Clinical research studies routinely employ several health-related
quality-of-life instruments in parallel to measure different types
of patient-reported outcomes. Specific instruments record the
patients’ symptoms or functioning and detect changes relevant
to the diagnosis and management of particular medical condi-
tions. Generic measures of health are independent of condition
and enable the comparison of outcomes with those of other
interventions or with other patient groups. Certain generic
instruments permit the derivation of health state utilities,
thereby allowing patient-reported outcomes to be incorporated
into cost-effectiveness analyses [1].
The range of generic instruments available to the medical
researcher is extensive, and choosing which to use alongside
specific instruments for a particular investigation requires con-
sideration under various criteria [2]. One of these is responsive-
ness, the ability of the instrument to detect change over time
in relation to the characteristic being measured. Responsiveness
embodies the capacity to discriminate between patients in
states of health judged to be different by an external criterion.Responsiveness is of interest because we might doubt the con-
struct validity of a generic instrument that has a noticeably
poorer capacity to discriminate and a lower responsiveness to
change than that of a specific instrument. There is, moreover, an
important corollary for clinical trials. The sample size necessary
to detect a change in health status is a direct function of
the responsiveness of the instrument detecting the change [3].
It follows that the less responsive the instrument employed and
the poorer its capacity to discriminate, the larger is the sample
required. Thus, when using multiple instruments, the appropri-
ate sample size, and pari passu the cost of the trial, is determined
by the capability of the least responsive instrument. Alterna-
tively, a study powered for the most responsive instrument risks
being unable to detect outcomes measured by less responsive
instruments.
Intuition suggests that specific instruments must inevitably
be more responsive than generic ones in that the scope of what
they are measuring is narrower. Ten years ago, this was the
conclusion of a review of studies that had used parallel instru-
ments [4]. Over the intervening years, however, generic instru-
ments have proliferated and more generic-specific comparisonsSociety for Pharmacoeconomics and Outcomes Research (ISPOR).
, University of Nottingham, Nottingham NG7 2RD, UK.
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now grounds for believing that the relative responsiveness of
generic and specific instruments is not predetermined but varies
with the medical condition under consideration and the choice of
comparators. Relative responsiveness properties can be estab-
lished only by observation. For example, a lower responsiveness
for generic instruments relative to specific has been reported in
schizophrenia studies [5], although equivalent responsiveness
has been identified in studies of metastatic cancer [6] and back
surgery [7]. For low back pain, the full range of lower [8],
equivalent [9], and higher [10] responsiveness has been reported
for the generic instrument under investigation.
By using data from a UK trial of the management of low
back pain, we compared the responsiveness of the EuroQol
five-dimensional questionnaire (EQ-5D) instrument, a generic
measure of health-related quality of life, to that of two condition-
specific measures. These were the Brief Pain Inventory (BPI), which
records both pain intensity and its effect on functioning, and the
Oswestry Disability Index (ODI), an instrument specific to pain and
impairment associated with spinal disorders. Although the EQ-5D
and either the BPI or the ODI have been advocated as potential
pairings for some time [11] and have appeared together in earlier
back pain studies [12], few psychometric comparisons have been
carried out [13].Methods
Instruments
Each of the three instruments requires patient-reported ques-
tionnaire responses. Each of the specific instruments has been
validated in a variety of languages and clinical contexts and has
been endorsed by expert panels [14–16]. The BPI [17] has two
components: one assessing the primary symptom and one
assessing the effect of that symptom on functioning. It opens
by presenting the subject with four dimensions of pain intensity,
each to be rated on an 11-point linear scale ranging from ‘‘no
pain’’ (scored as 0) to ‘‘pain as bad as you can imagine’’ (scored
as 10). These dimensions assess the worst, the least, and the
average pain experienced over the previous 24 hours, along with
the current level of pain, in that order. The scores on these four
dimensions are totaled or averaged to provide a mean pain
intensity score. Thereafter, the subject indicates the extent to
which pain has interfered with each of seven dimensions
of functioning: general activity, mood, walking ability, work
performance, relationships, sleep, and enjoyment of life. Each
of these is scored on an 11-point linear scale ranging from ‘‘no
interference’’ (scoring 0) to ‘‘completely’’ (scoring 10). Scores on
these seven dimensions are totaled or averaged to provide a
mean pain interference score.
The ODI [18] combines symptom severity and functioning in a
single measure. It presents its subjects with 10 categories of
health-related quality-of-life and everyday activities: pain inten-
sity, personal care, lifting, walking, sitting, standing, sleeping, sex
life, social life, and traveling, in that order. For each category, six
statements describe different and increasing degrees of severity
or extent of incapacity. These have been assigned scores from
0 to 5, according to severity. Subjects select the statement (and
record the corresponding score) that best describes their own
circumstances. The overall ODI score is the mean of the 10
category scores, expressed as a percentage.
The EQ-5D [19] has become themost widely used health-related
quality-of-life instrument for obtaining health state utilities [20].
The questionnaire comprises two elements: a health state classi-
fication and a visual analogue scale (VAS). The subject describes his
or her own health-related quality of life by assigning one of threelevels of problem severity—none, some/moderate, severe, coded 1,
2, and 3, respectively—to each of five health domains or
dimensions—mobility, self-care, capacity to undertake usual activ-
ities, pain/discomfort, and anxiety/depression, in that order.
A subject’s state of health is thereafter described as a five-digit
vector; for example, 22213 implies some problems or limitations
with mobility, self-care, and usual activities and no pain or
discomfort but severe anxiety or depression. Any health state can
be converted to a single summary ‘‘index score’’ by using sets of
utility values derived from samples of the general population.
In the United Kingdom, for example, 22213 translates to an index
score of 0.21, relative to utilities of 1 and 0 for no reported health
problems (vector 11111) and death, respectively [21]. The extremes
of the VAS are ‘‘worst imaginable’’ and ‘‘best imaginable’’ health
state, represented as the scale end points of 0 and 100, respectively.
The VAS records the individual subject’s self-evaluated health,
whereas the index score, being derived from population weights,
can be regarded as the social valuation of a health state.
Data
The subjects from whom data were obtained were participants in
a study of epidural steroid injections to alleviate low back pain
that was conducted in Nottingham, England. At recruitment, each
subject completed a baseline array of questionnaires, which
included the BPI, the ODI, and the EQ-5D. After injection, each
subject was supplied with a questionnaire booklet containing
multiple copies of the instruments and was asked to complete the
same questionnaire array every 7 days for a further 12 weeks. The
process was then repeated: subjects completed a second baseline
questionnaire array, received a second injection and a second
booklet, and were asked to complete a second sequence of
questionnaire arrays. In principle, therefore, each subject would
complete up to 26 weekly questionnaires for each instrument.
These would appear as two sequences, each from week 0 (base-
line, preinjection) to week 12, and each sequence would provide
12 sets of week-to-week change scores. Some degree of incom-
plete adherence and withdrawal from the study was anticipated.
Details of the conduct of the study, including procedures for
ethical approval, have been provided elsewhere [22].
All questionnaire data were scored according to the instru-
ments’ conventional algorithms, and no imputations were made
for incomplete responses (i.e., incomplete questionnaires were
excluded). The BPI pain intensity scores lie in the range of 0 to 10,
whereas the ranges of BPI pain interference and the ODI scores
are both 0 to 100. Because the BPI and the ODI are measures of
illness, higher scores imply worse pain, more interference, or
greater disability. The EQ-5D index scores were calculated from
the vectors by using the UK tariff [21]. The nominal range of the
EQ-5D index scores is 0 to 1, but negative scores as low as 0.59
are possible for health states deemed to be worse than death. The
VAS range is 0 to 100. In contrast to the BPI and the ODI, the
EQ-5D is a measure of health and higher scores imply better health.
Analysis
An agreed definition of responsiveness remains elusive [23,24]
despite attempts at standardization [25]. For present purposes,
responsiveness is the ability of a measure to change over time,
judged against the corresponding change in a reference measure
[26]. This conception embodies the measure’s capacity to capture
any clinically important distinctions and health state changes
that have been signaled [27]. In line with differences in inter-
pretation over meaning, there exists a range of statistical indi-
cators of responsiveness. To provide as much illumination as
possible on the performances of the instruments, we undertook
not one but a range of analyses.
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the proposition that an instrument sensitive to cross-sectional
differences in health between subjects is likely to be sensitive to
change in subjects as well [28]. Second, we correlated week-by-
week changes in the scores on the grounds that higher correla-
tions suggest more similarity in responsiveness [29]. Third, we
calculated the standardized response mean (SRM) associated
with each instrument as a metric of signal quality. Many of the
test statistics constructed to assess responsiveness are related
mathematically, and the SRM is deemed equivalent to all and
superior to some [30,31]. The SRM is the mean change in scores
over time divided by the SD of the measured changes.
Fourth, receiver operating characteristic (ROC) curves can
describe an instrument’s ability to detect change against an
external criterion [32] and we performed ROC curve analyses to
determine each instrument’s capacity to classify change. Each of
the reference outcomes (pain increase and pain decrease, as
measured by positive and negative changes in BPI pain intensity)
was predicted from changes in one of the other measures in turn
by means of bivariate logistic regression. Each model provided
data to plot an ROC curve, the area under which represented the
probability that the measure had correctly classified patients
whose pain status has improved or deteriorated as assessed
by the reference. An area of 1 indicates that the instrument
classifies perfectly, whereas an area of 0.5 indicates that it
performs no better than a random classification [33]. Fifth, the
responsiveness of generic to specific instrument operates in
reverse as well, in the sense that we would expect that whenever
change is recorded by the generic instrument, change is also
signaled by the specific instrument. We therefore compared
changes in the ODI and BPI scores with changes in the EQ-5D
severity for each of the five EQ-5D dimensions.
Sixth, ranges of pain severities, as assessed by the BPI
intensity scale, have been proposed to triage pain into clinically
meaningful categories—mild, moderate, or severe. A generic
instrument that is incapable of discriminating between severity
categories deemed clinically relevant could not be considered
responsive to severity. Opinions on severity classification have
varied. We followed those used in psychometric studies [34–37]
and classified mean BPI intensity scores as less than 5 for mild
pain, greater than or equal to 5 to less than 7 for moderate, and
greater than or equal to 7 for severe. This having been said,
studies estimating mean EQ-5D index scores by severity have
favored a definition of mild pain as less than 4, with moderate at
greater than or equal to 4 to less than 7. We therefore replicated
the analysis by using the lower cutoff to facilitate comparison.
Seventh, there exists for all instruments a minimum important
clinical distance (MICD), the smallest change in score that patients
would perceive as beneficial or detrimental and that could justify
a change in management [38]. A change of 2 points (or 30%) has
been proposed as the MICD for the BPI intensity score [39,40].
Changes of 10 or more points have been suggested for the ODI
[39,41], although minimum values of up to 16 have been defended
[42,43]. A comparison of eight longitudinal studies of conditions
including back pain, arthritis, and heart disease identified an
average of 0.08 for the MICD of the EQ-5D index, with a maximum
of 0.14 [44]. MICDs for EQ-5D’s VAS are rarely reported in psycho-
metric studies, an exception being one for cancer patients [45],
which suggested scores between 7 and 10. The extent to which the
different instruments’ MICDs identify cases consistently is an
indication of their classification capacities.Results
Thirty-seven subjects returned two series of questionnaires and
a further two each returned one series only, implying a nominalsample size of 76 sets of observations for each of weeks 0 to 12.
Consistent with the findings of previous research [46,47], the trial
determined that an epidural steroid injection produced only
short-term relief from pain [22]. Pain, pain-related functioning,
and quality of life improved significantly from weeks 0 to week 2
according to all the measures. For each instrument, the mean
change over this period exceeded its threshold MICD. Table 1
summarizes the relevant data. After week 2, the trends reversed.
By week 12, the mean score recorded by each instrument was not
significantly different from that recorded at baseline.
The frequency of questionnaires and the numbers to be
completed implied a theoretical maximum of 988 observations
of score for each instrument and a maximum of 912 week-by-
week changes in score. Not all patients completed all question-
naires, however, and Table 2 gives the actual numbers of observa-
tions analyzed. Inadequate completion rates were uniformly low
(o3%) for all instruments except the VAS (9.2%). Fifty different
EQ-5D health states were represented, and negative index scores
were reported in 17.1% (n ¼ 171) of the observations. Within these,
all five health domains had been classified at the second or
third severity level, with the exception of nine reports (from four
different subjects) of no problems on the self-care dimension. The
EQ-5D has been shown to be less responsive [48] when many
subjects report extreme health states (vectors 11111 or 33333), but
in the present study, only 2.7% of all observations fell into this
category. Also given in Table 2 is the distribution of the direction
of the changes measured by each instrument. In this context, a
negative change means a reduction in pain and its effect on
functioning for the ODI and the BPI but a deterioration in health-
related quality of life for the EQ-5D. The EQ-5D index, determined
by the problem severity classification, recorded far fewer positive
or negative changes than did the other instruments.
Table 2 also lists coefficients of correlations both between the
weekly score values and between the week-by-week changes in
score values. With the exceptions of the BPI intensity-
interference pairing and all cases involving the EQ-5D index,
changes in scores were more highly intercorrelated than were the
actual scores themselves. All differences between correlation
coefficients were subjected to a test for correlated correlations
[49], with BPI intensity as the comparator. Considering the actual
scores, the correlations between each part of the BPI and the
EQ-5D index score were at least as high as the corresponding
correlations with the other specific instrument, the ODI. Correla-
tions involving the VAS were invariably the lowest. Considering
the changes in scores, the three correlations between the specific
measures were higher than those between a specific measure
and either generic measure and higher still than the correlation
between changes measured by the two components of the
generic measure. Comparing the six correlation coefficients
between the two components of the EQ-5D instrument (index
and VAS) and the specific instruments, it was only for changes in
BPI pain intensity that no significant difference was observable.
In all other cases, the correlations between VAS scores and
condition-specific scores were significantly less than those
between index scores and condition-specific scores.
Finally, Table 2 gives SRMs and the area under the curve (AUC)
for the ROC curve analysis. The SRM for the EQ-5D index was
significantly lower than those for both the VAS and the specific
measures. The ROC curve results indicated that the specific
instruments were significantly superior classifiers of pain sever-
ity to the EQ-5D, although of the two components, neither the
index nor the VAS was the better performer.
Table 3 lists proportions, means, and 95% confidence intervals
(CIs) for changes in the two BPI scores, in the ODI scores, and in
the VAS scores for responses grouped according to a change in
one level of severity for each of the five EQ-5D dimensions.
Table 3 indicates, for example, that an increase in the severity
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VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 1 2 4 – 1 3 2 127of mobility problems by one EQ-5D level was associated with a
mean rise in the ODI score of 13.7 (95% CI 8.9–18.5) whereas an
improvement in pain or distress by one level was associated with
a fall in the BPI intensity score of 1.7 (95% CI 1.4–2.0). A change
in level was recorded most frequently on the pain/distress
dimension and least frequently on the mobility dimension. The
low absolute frequency of reported change in EQ-5D classification
contrasts with the high frequency of change as assessed by other
instruments (Table 2).
Considering each scale in turn, the CIs about the means by
EQ-5D severity level failed to intersect for any of the five
dimensions. For each dimension, when the EQ-5D instrument
indicated no change in problem severity the CIs indicated that
mean changes in scores on the remaining four scales were not
significantly different from 0. When the severity of the EQ-5D
problem increased, mean changes in BPI and ODI scores were
significantly positive, and when the severity of the problem
decreased, mean changes in BPI and ODI scores were significantly
negative. The opposite was the case with respect to the VAS
score. Estimates in Table 3 exclude a small number of responses
involving a change across two levels (two responses for the pain/
distress dimension and five for anxiety/depression). For all scales,
the changes in all such cases were even more extreme than for
the one-level cases.
Table 4 lists numbers of responses, mean scores, and asso-
ciated CIs by BPI severity bandings. In no cases did the CIs
intersect, implying that each of the other measures was capable
of discriminating between BPI severities. Redefining the border-
line between mild pain and moderate pain as 4 rather than
5 redistributed 58 observations from mild to moderate for the
EQ-5D index estimations. As a result, the mean index score rose
slightly in both categories: to 0.64 (95% CI 0.61–0.66) for mild and
to 0.49 (95% CI 0.47–0.52) for moderate.
Finally, with respect to correspondence in classification, we
earlier assumed MICDs for changes in BPI pain intensity, ODI
score, EQ-5D index score, and VAS score to be 2, 10, 0.08, and 10,
respectively. BPI pain intensity was taken as the reference
category. Using each measure in turn and its corresponding
threshold value, the ODI, the EQ-5D index, and the VAS would
signal an MICD in a patient whose pain had improved by 2 or
more BPI points in 61.4%, 64.0%, and 71.3% of the cases,
respectively. The same three measures would, according to their
own thresholds, incorrectly identify a 2-or-more-point pain
change in 12.3%, 27.6%, and 19.5% of the cases, respectively. Were
the ODI threshold to be raised to 16, 55.2% of the BPI-defined
MICDs would be identified correctly and only 3.2% of the cases
would be identified incorrectly. Were the EQ-5D index score
threshold to be raised to 0.14, 58.3% of the BPI-defined MICDs
would be identified but 24.3% would be identified incorrectly.
Compared with the EQ-5D index, the ODI appeared to be a more
specific, but less sensitive, detector of a BPI-defined MICD.Discussion
Our observed correlations (Table 2) between the EQ-5D index
score and the BPI intensity and interference scores essentially
replicate those discovered in a diabetic neuropathy study
(r ¼ 0.58 and 0.67, respectively) [50]. The correlation coefficient
between the EQ-5D index and ODI scores was similar to the
correlation (r ¼ 0.64) identified in a multicountry assessment
of leg pain [51]. A Norwegian back pain study [7] identified a
higher correlation (r ¼ 0.74), although other investigators have
reported lower ones. A Canadian back pain study reported
correlation coefficients of 0.36 and 0.46 at two different time
points [52], although the authors expressed concern that the
UK EQ-5D value set used to construct the index scores was
Table 2 – Correlations and responsiveness.
BPI, Brief Pain Inventory; CI, confidence interval; EQ-5D, EuroQol five-dimensional questionnaire; ODI, Oswestry Disability Index; ROC, receiver
operating characteristic; VAS, visual analogue scale.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 1 2 4 – 1 3 2128inappropriate for Canadian subjects. Correlation coefficients of
less than 0.25 were reported for two time points in a Spanish back
pain study [53]. This result was ascribed to problems with the
ODI in the particular context, because two other context-specific
measures were strongly correlated with the EQ-5D index (r4 0.6)
but poorly correlated with the ODI scores.
Table 2 indicates that the correlations between the scores
from each of the specific instruments (ODI or BPI) and the generic
instrument (EQ-5D) were slightly higher than the correlations
between the scores of two specific instruments (ODI and either
part of the BPI). The opposite, however, was the case with respect
to association between changes. Generic-specific correlations
were evidently lower than interspecific correlations. The mean-
ing of the size of correlation coefficients is subjective, although
coefficients in excess of 0.5 have been considered ‘‘large’’ [54]
or indicative of a ‘‘close’’ relationship in the case of correlations
between changes [55]. All correlations except those involving the
VAS fell into this category. None of the studies cited above
reported correlations between changes in scores, providing no
basis for comparison with our results.
In our study, the SRM for the EQ-5D index was the lowest of
the instruments being considered (Table 2), although it was
similar to, or higher than, SRMs identified by some other
researchers. An arthritis study [56] estimated an SRM of 0.64,
and a review of eight studies of various medical conditions
reported no SRMs greater than 0.42 [44]. The highest SRM
reported for the EQ-5D index in a generic-specific comparison
assessing changes in low back pain over different time periods
was 0.51 [8]. This estimate was significantly lower than the SRMs
reported for the specific instruments, and a lower SRM for the
index relative to the ODI has also been reported in a UK spine
stabilization study [57].
The size of the area under the ROC curve is not invariant to
the choice of comparators. For example, a study of fractures [58]
reported AUCs for the EQ-5D index between 0.71 and 0.81 for
pairwise comparisons between groups in which patients had
perceived either small or large improvements or deteriorations.Possibly the most useful comparison, therefore, is with studies
where AUCs for different instruments have been presented. First,
a study of low back pain [57] using the EQ-5D index and the ODI
estimated AUCs of 0.75 and 0.83, respectively, for groups perceiv-
ing improvement versus no improvement in health status.
Second, a study of two types of spinal surgery [59] using the
EQ-5D index and the ODI estimated AUCs of 0.60 and 0.74,
respectively, and 0.65 and 0.69, respectively; again, the criterion
was patients perceiving improvement versus no improvement in
health status. Our own estimates (Table 2) were within the range
bounded by these two previous studies and, in all three cases, the
AUC for the ODI exceeded that of the EQ-5D index.
We observed a severity gradient with the BPI-specific instru-
ment, whereby clinically significant categories of mild, moderate,
and severe BPI intensity translated into progressively and sig-
nificantly lower mean EQ-5D index scores. This finding parallels
those of five other pain studies, each of which used the UK value
set and a mild/moderate cutoff of 4 as opposed to 5 [60–64]. The
range of mean index scores reported in these studies was 0.67
to 0.72 for mild pain, 0.46 to 0.63 for moderate, and 0.16 to 0.30 for
severe. Our sample produced mean scores within these ranges
for moderate and severe pain, although, for mild pain, the mean
was below the range minimum. The severity gradient also trans-
lated into differences between mean VAS scores, as in an earlier
Swedish study of prostate cancer [65]. Reversing the direction of
the argument, we found that an increase or a decrease in severity
level on any of the five EQ-5D dimensions was associated with
significant changes (with appropriate signs) in the means of all
the condition-specific scores. Equally importantly, no change in
severity in any EQ-5D dimension was associated with no change
in the context-specific scores. Clinically important changes in
both the BPI and the ODI were also accompanied by significant
changes in the EQ-5D index.
The EQ-5D classification method was sufficient to enable the
index score to discriminate between important clinical differ-
ences (Tables 1 and 4), yet the specific instruments (BPI inter-
ference and the ODI) were characterized by higher SRMs, AUCs,
Table 3 – Changes in mean scores resulting from changes in severity on the EQ-5D dimensions.
EQ-5D severity change % of scores
changing
BPI intensity BPI interference ODI EQ-5D VAS
Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI
Mobility
1 4.1 1.8 2.4 to 1.2 15.2 19.1 to 11.2 12.1 17.1 to 7.2 19.7 11.2 to 28.2
0 91.9 0.0 0.1 to 0.1 0.1 0.7 to 0.9 0.1 0.5 to 0.6 0.2 1.1 to 0.7
1 4.1 1.4 0.8 to 1.9 14.5 9.4 to 19.6 13.7 8.9 to 18.5 18.7 26.6 to 10.8
Self-care
1 4.1 2.2 2.9 to 1.4 16.9 21.8 to 12.0 14.2 19.2 to 9.3 12.8 1.2 to 24.4
0 90.8 0.0 0.1 to 0.1 0.3 0.5 to 1.1 0.2 0.4 to 0.8 0.2 1.1 to 0.7
1 5.1 1.1 0.6 to 1.6 9.3 4.4 to 14.3 10.0 5.8 to 14.2 9.1 16.0 to 2.2
Usual activities
1 7.5 1.6 2.0 to 1.1 14.2 18.0 to 10.3 9.6 12.8 to 6.3 18.3 12.6 to 24.0
0 85.3 0.0 0.1 to 0.1 0.1 0.7 to 0.8 0.0 0.6 to 0.5 0.4 1.3 to 0.4
1 7.2 1.6 1.3 to 2.0 14.3 10.5 to 18.2 11.7 8.4 to 15.0 15.8 20.9 to 10.8
Pain/distress
1 12.3 1.7 2.0 to 1.4 12.8 15.6 to 10.0 9.3 11.5 to 7.1 10.5 6.4 to 14.6
0 75.7 0.0 0.1 to 0.1 0.1 0.7 to 0.8 0.0 0.5 to 0.5 0.5 1.4 to 0.4
1 12.0 1.5 1.2 to 1.8 12.9 10.3 to 15.5 10.3 8.3 to 12.3 9.0 12.6 to 5.4
Anxiety/depression
1 8.4 1.3 1.7 to 0.9 12.5 16.0 to 9.0 7.6 10.1 to 5.1 8.9 4.2 to 13.5
0 83.1 0.0 0.1 to 0.1 0.2 0.6 to 1.0 0.1 0.5 to 0.7 0.4 1.4 to 0.6
1 8.4 1.0 0.7 to 1.3 11.2 7.7 to 14.7 7.4 4.3 to 10.4 7.2 11.1 to 3.4
BPI, Brief Pain Inventory; CI, confidence interval; EQ-5D, EuroQol five-dimensional questionnaire; ODI, Oswestry Disability Index; VAS, visual analogue scale.
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Table 4 – Mean scores by BPI pain severity.
BPI severity Mean 95% CI
BPI intensity Mild 3.2 3.1–3.3
Moderate 5.9 5.9–6.0
Severe 8.0 7.9–8.1
BPI interference Mild 30.4 28.2–32.7
Moderate 52.2 50.8–53.6
Severe 66.1 64.3–67.9
ODI Mild 39.3 37.5–41.1
Moderate 52.2 50.7–53.7
Severe 58.8 57.1–60.5
EQ-5D index Mild 0.62 0.60–0.64
Moderate 0.48 0.45–0.51
Severe 0.18 0.15–0.22
EQ-5D VAS Mild 64.2 61.6–66.8
Moderate 47.4 45.7–49.1
Severe 39.1 36.4–41.9
BPI, Brief Pain Inventory; CI, confidence interval; EQ-5D, EuroQol
five-dimensional questionnaire; ODI, Oswestry Disability Index;
VAS, visual analogue scale.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 1 2 4 – 1 3 2130and correlations between changes (Table 2). Our data suggest two
factors explaining this discrepancy. First, specific instruments
tend to be designed for greater measurement sensitivity. The
EQ-5D instrument assesses pain at three levels, whereas the BPI
assesses at 11. A modest change in pain sufficient to be recorded
on the specific scale might therefore be insufficient to be
recorded on the coarser, generic, scale. Indeed, the proportion
of records indicating no week-to-week change was more than
three times greater for the EQ-5D classification than for the BPI,
as noted earlier. Triaging BPI pain intensity (Table 4), however,
coarsens the instrument and reduces its variability to that of the
generic instrument. Second, any generic measure typically com-
prises assessment of a number of symptoms or characteristics,
any one of which could, in principle, be the subject of specific
measurement. For example, the EQ-5D instrument assesses five
types of health problem, one of which is pain, whereas the BPI
assesses only pain. If, for any patient, pain failed to affect any
other symptom, these other dimensions would be reported as
unchanged, despite pain changing. Relative to the specific instru-
ment, therefore, the generic instrument would record a smaller
change and one in proportion to the importance attached to pain
within quality of life overall.
Combining these arguments, it follows that the generic-
specific difference in responsiveness will be smaller if the
symptom measured by the specific instrument 1) carries greater
weight in the array of arguments measured by the generic
instrument, 2) is associated with other symptoms that trigger
additional dimensions of the generic instrument, and 3) is
classified on the generic scale with the same or greater degrees
of gradation as on the specific scale. Generic responsiveness
would approach that of specific when changes in symptoms were
more pronounced and comorbidities were more extensive [66].
With respect to 1), we note that pain/distress has the highest
marginal effect on index scores among the five EQ-5D dimen-
sions according to the UK algorithm. With respect to 3), a revised
version of the EQ-5D instrument is under development, whereby
the three severity levels are to be replaced by five. On the basis of
the arguments above, this revision could be expected to lead
to increased discriminatory power and responsiveness, a predic-
tion borne out by a pilot experiment [67].
We reaffirm that this study was conducted on UK patients by
using the UK value set for health state utilities. EQ-5D value sets
are population –specific, and utilities assigned to the same healthstate may differ by country. For example, the UK population
ascribes greater importance to the pain and anxiety dimensions
and less to mobility and self-care than does the Spanish popula-
tion, although the Spanish population associates greater negative
weights to the worst health states [68]. Relative to those of the
United Kingdom, the average utilities for all health states in the
United States are higher, as is the value of the poorest state,
implying that a given change in health state has a smaller effect
on utility gain or loss [69]. It follows that the responsiveness
properties and discriminatory power of the index score as
calculated in this study might not be reproduced in other
countries where the UK value set is considered inappropriate.
The data reveal disparities between the two components of
the EQ-5D generic instrument. The SRM of the VAS was higher
than that of the index, yet the AUCs of both components were
similar. The correlations between the specific measures and the
VAS were always lower than the equivalent correlations involving
the index. The correlation of score changes between the two
components of the generic measure was lower than any correla-
tion between one of the generic components and any of the
specific measures. In contrast, the two components of the
BPI-specific instrument exhibited very similar responsiveness
properties and a close association. A lack of correspondence
between the VAS and the index has been observed before in pain-
related studies [70,71], with respondents often reporting severe
problems in the classification yet offering high scores
on the VAS. The causes of the weak association remain under-
researched, although we conjecture that it might be explained by
four coincident factors.
First, utilities for each of the EQ-5D’s health state vectors
are informed by opinions elicited from members of the public.
In contrast to patients completing the VAS, very few of these
members will actually be in the state which they are valuing.
There is therefore a potential for a discrepancy between the
perceptions of disutility of a health problem on the parts of those
imagining them and those experiencing them. For example,
a Spanish study found that the average disutility from back pain,
as assessed by the population, was higher than that assessed by
those suffering [71]. The second factor is dimensionality. Of all
the measures discussed, EQ-5D VAS is the most generic. Although
the BPI is limited to recording on the pain dimension and the
index score is derived from five specified dimensions including
pain, the VAS is unbounded. It can therefore encompass as many
different dimensions of health as the respondent chooses to
envisage, all reduced to a single value. There is no reason to
presume that different respondents choose the same aspects
and, even if they do, accord to them the same weights. Third,
recent research suggests that the individual’s VAS response is
influenced not only by his or her state of health but also by
personal characteristics, such as psychological disposition, age,
sex, education, and race [72–74]. Fourth, being required to
represent the severity of a health problem by spatial distance
rather than by numerical scale places different cognitive
demands on respondents and might not produce an equivalent
response [75]. The lower response rate for the VAS in this study,
in comparison with the other measures, suggests that some
respondents may have found the task of representing their
health spatially and, without the aid of dimensional cues, more
challenging.
This research has limitations. We opted for the self-comple-
tion of questionnaires, anticipating an unwillingness on the part
of patients to return regularly to the clinic, purely for the
purposes of our research. Although patients received instruction
in questionnaire completion and were contacted regularly, data
collection was therefore unmonitored. We relied on individuals
to complete the instruments at the appointed times, but the
fabrication of evidence and erratic recording practices cannot
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 1 2 4 – 1 3 2 131be ruled out. Repeated observations enabled us to generate a
large number of observations from a small sample of patients.
Nevertheless, the small sample size prevented any analysis
involving the characteristics of individual patients, thereby mak-
ing it impossible for us to explore, for example, the index-VAS
divergences noted above.
Finally, specific instruments and generic instruments are neither
rivals nor substitutes, because they fulfill different functions. Pain as
assessed by specific instruments is only one of a number of
dimensions of the health-related quality of life or health state utility
assessed by generic instruments. It follows that studies that hope to
produce results that are useful both clinically and economically need
to employ both specific and generic instruments in parallel. It is
important to stress that our combination of the BPI and the ODI
accompanied by the EQ-5D instrument was only one possible
combination of such instruments and alternative combinations
could have been chosen in this context. The six-dimensional health
state short form (derived from the SF-36) (SF-6D), for example, is a
rival to the EQ-5D instrument in generating utilities, although the
two instruments are not perfect substitutes. When used with the
same patients, they typically produce different distributions of utility
scores [76]. For both patients with arthritis [77,78] and low back pain
[79], relative responsiveness evidently depends on the direction of
change. The SF-6D appears more responsive to improvements in a
patient’s condition, whereas the EQ-5D instrument is more respon-
sive to deterioration. For a given change in health status, the EQ-5D
instrument records a higher utility change than does the SF-6D and,
other things remaining equal, evaluations using the EQ-5D instru-
ment will produce more favorable cost-effectiveness ratios. We note
this for two reasons. First, the findings of this article report
comparative responsiveness and constitute neither an endorsement
nor a renunciation of the particular combination of generic and
specific instruments used. Second, there is no reason to suppose
that the comparative responsiveness of alternative specific-generic
combinations would be the same as that identified here.Conclusions
Our results indicate that on the basis of a sample of patients with
low back pain, the EQ-5D index scored according to the UK value
set is less responsive than instruments specific to pain measure-
ment using conventional indicators. The difference arises from
the EQ-5D instrument’s more limited gradation of severity and
its multidimensionality. Even so, the instrument proved itself
capable of indicating important changes. In so doing, it was
favored by the conditions and context of the comparison—a
proportion of changes were large enough to be recognized by
the classification scheme, and of all the five dimensions, a
change in pain severity has the greatest effect on UK’s index
score. Although nominally joint components of a single generic
instrument, EQ-5D’s VAS and the classification scheme do not
perform in the same fashion psychometrically and may actually
be measuring conceptually different outcomes.
Source of financial support: This work was funded by the
Department of Anaesthesia, Nottingham City Hospital.
R E F E R E N C E S[1] Patrick DL, Deyo RA. Generic and disease-specific measures in
assessing health status and quality of life. Med Care 1989;
27(Suppl):S217–32.
[2] Fitzpatrick R, Davey C, Buxton MJ, et al. Evaluating patient-based
outcome measures for use in clinical trials. Health Technol Assess
1998;2:1–74.
[3] Guyatt G, Walter S, Norman G. Measuring change over time: assessing
the usefulness of evaluative instruments. J Chronic Dis 1987;40:171–8.[4] Wiebe S, Guyatt G, Weaver B, et al. Comparative responsiveness of
generic and specific quality-of-life instruments. J Clin Epidemiol
2003;56:52–60.
[5] Papaioannou D, Brazier J, Parry G. How valid and responsive are generic
health status measures, such as EQ-5D and SF-36, in schizophrenia?
Value Health 2011;14:907–20.
[6] Krabbe PF, Peerenboom L, Langenhoff BS, et al. Responsiveness of the
generic EQ-5D summary measure compared to the disease-specific
EORTC QLQ C-30. Qual Life Res 2004;13:1247–53.
[7] Solberg TK, Olsen J-A, Ingebrigtsen T, et al. Health-related quality of life
assessment by the EuroQol-5D can provide cost-utility data in the field
of low-back surgery. Eur Spine J 2005;14:1000–7.
[8] Garratt AM, Moffett JK, Farrin AJ. Responsiveness of generic and
specific measures of health outcome in low back pain. Spine
2001;26:71–7.
[9] Grotle M, Brox JI, VØllestad NK. Concurrent comparison of
responsiveness in pain and functional status measurements used for
patients with low back pain. Spine 2004;29:E492–501.
[10] Walsh TL, Hanscom B, Lurie JD, et al. Is a condition-specific instrument
for patients with low back pain/leg symptoms really necessary? The
responsiveness of the Oswestry Disability Index, MODEMS, and the
SF-36. Spine 2003;28:607–15.
[11] Deyo RA, Battie M, Beurskens AJ, et al. Outcome measures for low back
pain research: a proposal for standardized use. Spine 1998;23:2003–13.
[12] Chapman JR, Norvell DC, Hermsmeyer JT, et al. Evaluating common
outcomes for measuring treatment success for chronic low back pain.
Spine 2011;36(Suppl):S54–68.
[13] DeVine J, Norvell DC, Ecker E, et al. Evaluating the correlation and
responsiveness of patient-reported pain with function and quality-of-
life outcomes after spine surgery. Spine 2011;36(Suppl):S69–74.
[14] Bombardier C. Outcome assessments in the evaluation of treatment of
spinal disorders: summary and general recommendations. Spine
2000;25:3100–3.
[15] Caraceni A, Cherny N, Fainsinger R, et al. Pain measurement tools and
methods in clinical research in palliative care: recommendations of an
Expert Working Group of the European Association of Palliative Care.
J Pain Symptom Manage 2002;23:239–55.
[16] Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical
importance of treatment outcomes in chronic pain clinical trials:
IMMPACT recommendations. J Pain 2008;9:105–21.
[17] Tan G, Jensen MP, Thornby JI, et al. Validation of the Brief Pain
Inventory for chronic nonmalignant pain. J Pain 2004;5:133–7.
[18] Fairbank JCT, Pynsent PB. The Oswestry Disability Index. Spine 2000;
25:2940–53.
[19] Rabin R, Oemar M, Oppe M. EQ-5D-3L User Guide, version 4.0.
Rotterdam: EuroQoL Group, 2011.
[20] Brazier J. Valuing health states for use in cost-effectiveness analysis.
Pharmacoeconomics 2008;26:769–79.
[21] Dolan P. Modeling valuations for EuroQol health states. Med Care
1997;35:1095–108.
[22] McCahon RA, Ravenscroft A, Hodgkinson V, et al. A pilot study of the
dose-response of caudal methylprednisolone with levobupivacaine in
chronic lower back pain. Anaesthesia 2011;66:595–603.
[23] Beaton DE, Bombardier C, Katz JN, et al. A taxonomy for
responsiveness. J Clin Epidemiol 2001;54:1204–17.
[24] Terwee CB, Dekker FW, Wiersinga WM, et al. On assessing
responsiveness of health-related quality of life instruments: guidelines
for instrument evaluation. Qual Life Res 2003;12:349–62.
[25] Mokkink LB, Terwee CB, Patrick DL, et al. The COSMIN study reached
international consensus on taxonomy, terminology, and definitions of
measurement properties for health-related patient-reported outcomes.
J Clin Epidemiol 2010;63:737–45.
[26] Husted JA, Cook RJ, Farewell VT, et al. Methods for assessing
responsiveness: a critical review and recommendations. J Clin
Epidemiol 2000;53:459–68.
[27] Liang MH. Longitudinal construct validity: establishment of clinical
meaning in patient evaluative instruments. Med Care 2000;38:II84–90.
[28] Lindeboom R, Sprangers MA, Zwinderman AH. Responsiveness: a
reinvention of the wheel? Health Qual Life Outcomes 2005;3:8.
[29] Weatherall M, McPherson K, Taylor W, et al. Avoiding pitfalls of
correlation coefficients in the assessment of measurement
instruments in rehabilitation research. Clin Rehabil 2004;18:186–94.
[30] Zou GY. Quantifying responsiveness of quality of life measures without
an external criterion. Qual Life Res 2005;14:1545–52.
[31] Norman GR, Wyrwich KW, Patrick DL. The mathematical relationship
among different forms of responsiveness coefficients. Qual Life Res
2007;16:815–22.
[32] Deyo RA, Centor RM. Assessing the responsiveness of functional scales
to clinical change: an analogy to diagnostic test performance. J Chronic
Dis 1986;39:897–906.
[33] Fawcett T. An introduction to ROC analysis. Pattern Recognit Lett
2006;27:861–74.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 1 2 4 – 1 3 2132[34] Serlin RC, Mendoza TR, Nakamura Y, et al. When is cancer pain mild,
moderate or severe? Grading pain severity by its interference with
function. Pain 1995;61:277–84.
[35] Palos GR, Mendoza TR, Mobley GM, et al. Asking the community about
cutpoints used to describe mild, moderate, and severe pain. J Pain
2006;7:49–56.
[36] Li KK, Harris K, Hadi S, et al. What should be the optimal cut points for
mild, moderate, and severe pain? J Palliat Med 2007;10: 1388–46.
[37] Hoffman DL, Sadosky A, Dukes EM, et al. How do changes in pain
severity levels correspond to changes in health status and function in
patients with painful diabetic peripheral neuropathy? Pain 2010;
149:194–201.
[38] Jaeschke R, Singer J, Guyatt GH. Measurement of health status:
ascertaining the minimal clinically important difference. Control Clin
Trials 1989;10:407–15.
[39] Ostelo RWJG, Deyo RA, Stratford P, et al. Interpreting change scores for
pain and functional status in low back pain: towards international
consensus regarding minimal important change. Spine 2008;33:90–4.
[40] Mathias SD, Crosby RD, Qian Y, et al. Estimating minimally important
differences for the worst pain rating of the Brief Pain Inventory–Short
Form. J Support Oncol 2011;9:72–8.
[41] Ha¨gg O, Fritzell P, Nordwall A. The clinical importance of changes in
outcome scores after treatment for chronic low back pain. Eur Spine J
2003;12:12–20.
[42] Lauridsen HH, Hartvigsen J, Manniche C, et al. Responsiveness and
minimal clinically important difference for pain and disability
instruments in low back pain patients. BMC Musculoskelet Disord
2006;7:82.
[43] Copay AG, Glassman SD, Subach BR, et al. The minimum clinically
important difference in lumbar spine surgery patients: a choice of
methods using the Oswestry Disability Index, Medical Outcomes Study
questionnaire, Short Form 36, and Pain Scales. Spine J 2008;8:968–74.
[44] Walters SJ, Brazier JE. Comparison of the minimally important
difference for two health state utility measures: EQ-5D and SF-6D. Qual
Life Res 2005;14:1523–32.
[45] Pickard AS, Neary MP, Cella D. Estimation of minimally important
differences in EQ-5D utility and VAS scores in cancer. Health Qual Life
Outcomes 2007;5:70.
[46] Weinstein SM, Herring SA. Lumbar epidural steroid injections. Spine J
2003;3(Suppl):37S–44S.
[47] Armon C, Argoff CE, Samuels J, et al. Use of epidural steroid injections
to treat radicular lumbosacral pain: report of the Therapeutics and
Technology Assessment Subcommittee of the American Academy of
Neurology. Neurology 2007;68:723–9.
[48] Brazier J, Roberts J, Tsuchiya A, et al. A comparison of the EQ-5D and
SF-6D across seven patient groups. Health Econ 2004;13:873–84.
[49] Meng X-L, Rosenthal R, Rubin DB. Comparing correlated correlation
coefficients. Psychol Bull 1992;111:172–5.
[50] Zelman DC, Gore M, Dukes E, et al. Validation of a modified version of
the Brief Pain Inventory for painful diabetic peripheral neuropathy.
J Pain Symptom Manage 2005;29:401–10.
[51] Manca A, Eldabe S, Buchser E, et al. Relationship between health-
related quality of life, pain, and functional disability in neuropathic
pain patients with failed back surgery syndrome. Value Health
2010;13:95–102.
[52] Suarez-Almazor ME, Kendall C, Johnson JA, et al. Use of health status
measures in patients with low back pain in clinical settings:
comparison of specific, generic and preference-based instruments.
Rheumatology 2000;39:783–90.
[53] Kovacs FM, Abraira V, Zamora J, et al. Correlation between pain,
disability, and quality of life in patients with common low back pain.
Spine 2004;29:206–10.
[54] Hemphill JF. Interpreting the magnitudes of correlation coefficients.
Am Psychol 2003;58:78–9.
[55] Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of
life. Ann Intern Med 1993;118:622–9.
[56] Harrison MJ, Davies LM, Bansback NJ, et al. The comparative
responsiveness of the EQ-5D and SF-6D to change in patients with
inflammatory arthritis. Qual Life Res 2009;18:1195–205.[57] Campbell H, Rivero-Arias O, Johnston K, et al. Responsiveness of
objective, disease-specific and generic outcome measures in patients
with chronic low back pain: an assessment for improving, stable and
deteriorating pain. Spine 2006;31:815–22.
[58] Olerud P, Tidermark J, Ponzer S, et al. Responsiveness of the EQ-5D in
patients with proximal humeral fractures. J Shoulder Elbow Surg
2011;20:1200–6.
[59] Parker SL, Adogwa O, Paul AR, et al. Utility of minimum clinically
important difference in assessing pain, disability, and health state after
transforaminal lumbar interbody fusion for degenerative lumbar
spondylolisthesis. J Neurosurg Spine 2011;14:598–604.
[60] Gore M, Brandenburg NA, Dukes E, et al. Pain severity in diabetic
peripheral neuropathy is associated with patient functioning,
symptom levels of anxiety and depression, and sleep. J Pain Symptom
Manage 2005;30:374–85.
[61] McDermott AM, Toelle TR, Rowbotham DJ, et al. The burden of
neuropathic pain: results from a cross-sectional survey. Eur J Pain
2006;10:127–35.
[62] Oster G, Harding G, Dukes E, et al. Pain, medication use, and health-
related quality of life in older persons with postherpetic neuralgia:
results from a population-based survey. J Pain 2005;6:356–63.
[63] To¨lle T, Dukes E, Sadosky A. Patient burden of trigeminal neuralgia:
results from a cross-sectional survey of health state impairment and
treatment patterns in six European countries. Pain Pract 2006;6:153–60.
[64] van Seventer R, Sadosky A, Lucero M, et al. A cross-sectional survey of
health state impairment and treatment patterns in patients with
postherpetic neuralgia. Age Ageing 2006;35:132–7.
[65] Sandblom G, Carlsson P, Sigsjo¨ P, et al. Pain and health-related quality
of life in a geographically defined population of men with prostate
cancer. Br J Cancer 2001;85:497–503.
[66] Slover J, Abdu WA, Hanscom B, et al. The impact of comorbidities on
the change in Short-Form 36 and Oswestry scores following lumbar
spine surgery. Spine 2006;31:1974–80.
[67] Pickard AS, De Leon MC, Kohlmann T, et al. Psychometric comparison
of the standard EQ-5D to a 5 level version in cancer patients. Med Care
2007;45:259–63.
[68] Badia A, Roset M, Herdman M, et al. A comparison of United Kingdom
and Spanish general population time trade-off values for EQ-5D health
states. Med Decis Making 2001;21:7–16.
[69] Luo N, Johnson JA, Shaw JW, et al. A comparison of EQ-5D index scores
derived from the US and UK population-based scoring functions. Med
Decis Making 2007;27:321–6.
[70] Wolfe F, Hawley DJ. Measurement of the quality of life in rheumatic
disorders using the EuroQoL. Br J Rheumatol 1997;36:786–93.
[71] Zamora J, Kovacs F, Abraira V, et al. The social tariff of EQ-5D is not
adequate to assess quality of life in patients with low back pain. Qual
Life Res 2007;16:523–31.
[72] Whynes DK. Correspondence between EQ-5D health state
classifications and EQ VAS scores. Health Qual Life Outcomes 2008;6:94.
[73] Chapman BP, Franks P, Duberstein PR, et al. Differences between
individual and societal health state valuations: any link with
personality? Med Care 2009;47:902–7.
[74] Perneger TV, Combescure C, Courvoisier DS. General population
reference values for the French version of the EuroQol EQ-5D health
utility instrument. Value Health 2010;13:631–5.
[75] Parkin D, Devlin N. Is there a case for using visual analogue scale
valuations in cost-utility analysis? Health Econ 2006;15:653–64.
[76] Whitehurst DGT, Bryan S, Lewis M. Systematic review and empirical
comparison of contemporaneous EQ-5D and SF-6D group mean scores.
Med Decis Making 2011;31:E34–44.
[77] Harrison MJ, Davies LM, Bansback NJ, et al. The comparative
responsiveness of the EQ-5D and SF-6D to change in patients with
inflammatory arthritis. Qual Life Res 2009;18:1195–205.
[78] Gaujoux-Viala C, Rat A-C. Guillemin F, et al. Responsiveness of EQ-5D
and SF-6D in patients with early arthritis: results from the ESPOIR
cohort. Ann Rheum Dis 2012;71:1478–83.
[79] SØgaard R, Christensen FB, Videbæk TS, et al. Interchangeability of the
EQ-5D and the SF-6D in long-lasting low back pain. Value Health
2009;12:606–12.
